

PHYTOCHEMICAL INVESTIGATION, ANTIBACTERIAL AND ANTI-INFLAMMATORY ACTIVITIES OF MUSSAENDA ELEGANS AND SMEATHMANNIA LAEVIGATA: CONTRIBUTION TO THE VALORIZATION OF GUINEAN MEDICINAL PLANTS.

Manuscript Info

Manuscript History

Received: xxxxxxxxxxxxxxxx
Final Accepted: xxxxxxxxxxxxxxxx
Published: xxxxxxxxxxxxxxxx

Key words:-

Mussaenda elegans, *Smeathmannia laevigata* , Phytochemical, antibacterial, anti-inflammatory..

Abstract

Plants in general and medicinal plants in particular, play an important role in human health. This work aims to study the phytochemical properties and evaluate the antibacterial and anti-inflammatory activity of *Mussaenda elegans* and of *Smeathmannia laevigata*, cultivated in the Republic of Guinea. Tannins, flavonoids, mucilage, and reducing compounds were identified in the leaves of both plants. *Mussaenda elegans* showed the highest content of phenolic compounds, with total polyphenols (22.006 ± 0.648 mg GAE/g), flavonoids (2.360 ± 0.110 mg QE/g), and tannins (4.087 ± 0.312 mg EC/g). For antibacterial activity, three strains were found to be sensitive to the hydroethanolic extract of *Mussaenda elegans*, namely, *Pseudomonas aeruginosa* and *Staphylococcus aureus* with aMIC of 1.25 mg/mL and *Candida albicans* (MIC 2.5 mg/mL). Hydroethanolic extract of *Smeathmannia laevigata* showed similar sensitivity against *Escherichia coli*, *Pseudomonas aeruginosa* and *Candida albicans* with MIC of 2.5 mg/mL. The anti-inflammatory activity observed for these two extracts was moderate. However, the *Mussaenda elegans* extract showed 18.29% inhibition, which is more promising than *Smeathmannia laevigata* extract's activity. These findings position *Smeathmannia laevigata* and *Mussaenda elegans* extracts as promising natural candidates for developing alternatives to conventional non-steroidal anti-inflammatory drugs, although their efficacy remains below the reference standard and requires further investigation to confirm their therapeutic potential and safety profile.

Copy Right, IJAR, 2019,. All rights reserved.

1 Introduction:-

2 The increasing ineffectiveness of antibacterial treatments (Klobucar and Brown , 2022; Prasad et al., 2021) is largely
3 attributed to the misuse and inappropriate use of antibiotics, which promotes the emergence and spread of
4 multidrug-resistant bacterial strains. Faced with this threat, the discovery and development of new molecules with
5 effective antibacterial biological activity against these pathogenic strains are essential, both to improve therapeutic
6 management and to limit the health and socioeconomic impact of bacterial resistance.

7 Inflammation (Nathan and Ding, 2010; Mack, 2018) is a complex and highly regulated biological response of the
8 body, involving the coordinated activation of immune cells and the release of pro-inflammatory mediators such as
9 cytokines, chemokines, prostaglandins, and reactive oxygen species. It is triggered in response to various pathogenic
10 stimuli, including microbial infections, tissue damage, and chemical insults, and plays a crucial role in tissue defense
11 and repair mechanisms. However, when this response becomes excessive or chronic, it contributes to the
12 development and progression of many inflammatory and degenerative diseases.

13 From a therapeutic standpoint, the management of inflammation relies primarily on the use of non-steroidal anti-
14 inflammatory drugs (NSAIDs), which act notably by inhibiting cyclooxygenases (COX-1 and COX-2), and steroidal
15 anti-inflammatory drugs (corticosteroids), which modulate the gene expression of multiple inflammatory mediators.
16 Despite their clinical efficacy, these synthetic molecules are frequently associated with significant adverse effects,

17 including gastrointestinal, renal, cardiovascular, and immunosuppressive disorders, thus limiting their long-term use
18 (Blain et al., 2000).

19 The Republic of Guinea is characterized by remarkable plant biodiversity, constituting an important source of
20 medicinal plants widely used in traditional medicine. Numerous studies have reported the use of these plant
21 resources in the management of various pathologies, including infertility (Bah et al., 2025) , dermatoses (Goumou
22 et al., 2018), malaria (Haba et al., 2022), hemorrhoids (Camara et al., 2024), oral and dental diseases (Camara et al.,
23 2023), and others. In this context, the present study aims to contribute to the scientific valorization of traditional
24 Guinean medicine through a phytochemical investigation, coupled with the evaluation of the biological activities
25 (antibacterial and anti-inflammatory activities) of two plant species: *Mussaenda elegans* and *Smeathmannia*
26 *laevigata* , commonly used in Upper Guinea in the treatment of dermatoses.

27

28 Materials and Methods

29 **Plant material:**

30 The leaves of *Mussaenda elegans* and *Smeathmannia laevigata* were harvested in the commune of Kankan
31 (Republic of Guinea) and then dried in the laboratory at Julius Nyerere University of Kankan. The dried leaves were
32 then ground into a powder and stored for analysis, which was carried out at the University of Abomey-Calavi in
33 Benin.

34 **Microorganisms**

35 Microorganism used in this study were constituted of *Enterococcus faecalis* , *Staphylococcus aureus* ; *Pseudomonas*
36 *aeruginosa* , *Escherichia coli* ; *Salmonella typhi* and *Candida albicans* .They were provided by the Bacteriology
37 section of the National Laboratory of the Ministry of Health in Benin.

38 **Animal material :** The animal material consists of male albino Wistar rats (180-210 g; n = 3 per group), raised
39 under the following conditions: 12 h light/dark; 22 ± 2 °C; humidity 50-60%; water and pellets ad libitum;
40 acclimatization 7 days.

41

42 Plant extracts preparation

43 Hydroethanolic (70%) extract of *M. elegans* and *S. laevigata* were prepared by exhaustive extraction for three
44 successive days in 70% ethanol. Extracts were filtered and concentrated using a rotary evaporator (BUCHI
45 Rotavapor RII). Filtrate were collected and stored at 4°C for further analysis.

46

47 Phytochemical screening

48 Phytochemical screening was carried out using standard methods described by Noudogbessi et al ., (2013) and
49 Olayé et al., (2018).

50 **Saponins**

51 The procedure involves preparing a decoction by boiling two (2) grams of dried, ground plant material in 100 mL of
52 distilled water for 30 minutes. After cooling and filtration, 1 mL, 2 mL, 3 mL, ..., 10 mL of the decoction are

53 introduced into 10 test tubes (1.3 cm internal diameter). The volume of extract in each tube is then adjusted to 10
54 mL with distilled water. After this, each tube is shaken. The tube is held horizontally for 15 seconds. The tubes are
55 then left to rest in a vertical position for 15 minutes, after which the height of the remaining moss is measured in
56 centimeters. If it is close to 1 cm in the tenth tube, then the moss index is calculated using the following formula: $I =$
57 Height of moss (in cm) in the tenth tube $\times 5/0.0X$ or $(1000/N)$, where N is the number of the tube where the moss
58 height is equal to 1 cm. The plant is considered to contain saponins when the index is greater than 100.

59 **Tannins**

60 Tannins are identified by preparing an aqueous infusion. Mix 5g of plant powder with 100mL of boiling distilled
61 water. This infusion is left to steep for 15 minutes, then filtered and rinsed with a little hot water to adjust the filtrate
62 volume to 100mL. A 5ml aliquot of this filtrate (5%) is then added to 1mL of 1% ferric chloride. The presence of
63 tannins is indicated by the observation of a greenish or bluish-black coloration.

64 **Mucilage**

65 Five milliliters of absolute ethanol are added to 1 milliliter of a 10% aqueous decoction prepared for 15 minutes.
66 The formation of a flocculent precipitate within the mixture is an indicator of the presence of mucilage.

67 **Anthraquinones**

68 In a test tube containing 2 mL of the extract, 5 mL of 10% ammonium hydroxide (NH₄OH) is added. The presence
69 of anthraquinones is characterized by the appearance of a yellow color.

70 **Flavonoids**

71 The identification of flavonoids was carried out by the cyanidin reaction consisting of adding 5 mL of hydrochloric
72 alcohol, a few magnesium shavings and 1 mL of isoamyl alcohol to a test tube containing 5 mL of filtrate of a 5%
73 infusion. The observation of a pink-orange, pink-purple or red color collected in the supernatant layer of isoamyl
74 alcohol reveals the presence of flavonoids respectively flavones, flavanones or flavonols and flavanonols.

75 **Alkaloids**

76 These are precipitation reactions. In acidic solutions at pH 1 or 2, alkaloid salts react with iodine compounds of
77 heavy metals to form characteristic colored precipitates. A sulfuric acid extract is prepared from 10 g of powdered
78 leaves, bark, or roots and 50 mL of concentrated H₂SO₄ diluted to 10% in a 250 mL Erlenmeyer flask. After maceration
79 for 24 hours at room temperature, the macerate is filtered through filter paper and washed with distilled water to
80 obtain 50 mL of filtrate. One (1) mL of filtrate is introduced into a test tube, to which approximately five drops of
81 Bouchardat's reagent are added. In the presence of alkaloids, a brown precipitate is obtained with Bouchardat's
82 reagent.

83

84 **Determination of phenolic content of the extracts**

85 **Total phenolic content**

86 Total phenolic content were evaluated using Folin–Ciocalteu technique (Koudoro et al., 2021). Briefly, 50 μ L of
87 plant extract previously prepared or reference compound (gallic acid) were mixing with 200 μ L of distilled water,
88 125 μ L of Folin–Ciocalteu reagent (1 N), and 625 μ L of sodium carbonate (20%, w/v). The mixture were kept in
89 dark for 30 minutes and then ultraviolet absorbance were measured at 760 nm using UV-visible spectrophotometer.

90 TPC was expressed as microgram (µg) of gallic acid equivalents per **milligram (mg) of dry extract (mg GAE/g)**
91 using a calibration curve plotted with pure gallic acid in a series of different concentrations.

92 **Total flavonoid content**

93 Aluminum chloride colorimetric method was used to determine the total flavonoid contents of plant extracts
94 (Koudoro et al., 2021). A volume of 50 µL of extracts were added to a solution containing 30 µL of 10% NaNO₂, 60
95 µL of 20% (AlCl₃, 6H₂O), 200 µL of 1 N NaOH, and 660 µL of distilled water. After mixing, the absorbance at
96 510 nm of each sample was determined with a UV-visible spectrophotometer. Standard calibration curve was
97 plotted with quercetin and total flavonoid content was expressed as microgram of quercetin equivalents **per**
98 **milligram of dry extract (mg QE/g)**.

99 **Tannins content**

100 The tannin content was determined according to the method described by Koudoro et al. (2021), which involves
101 mixing 50 µl of the extract with 3 mL of 4% vanilla in ethanol and 1.5 mL of fuming hydrochloric acid. Absorbance
102 was measured spectrophotometrically after 10 minutes of mixing in the dark at 510 nm against a blank without
103 extracts, which served as a reference. The results are expressed as mg catechin equivalent per g of extract (Olayé et
104 al., 2018).

105

106 **Determination of antimicrobial activity**

107 The antimicrobial test was performed according to the method described by Atindehou et al. (2013). Bacteria were
108 cultured aerobically at 37°C in Mueller-Hinton broth (MHB) for 18 hours. The hydroethanolic extract of each
109 sample was suspended in a DMSO /water mixture (10:90, v:v) and diluted to concentrations of 10, 5, 2.5, 1.25,
110 0.625, etc., mg/mL in MHB in 100 µL 96-well microplates. 100 µL of bacterial culture in logarithmic phase with a
111 concentration of 10⁶ CFU/mL at 620 nm was added. Each test was performed in triplicate. A positive DMSO/water
112 control and a negative control consisting of an MHB mixture without bacteria were performed. After 18 hours of
113 incubation at 37°C with shaking, the minimum inhibitory concentration (MIC) was determined by adding 40 µL of
114 iodonitrotetrazolium chloride at 0.2 mg/mL to each well. Bacterial growth was determined by a reddish-pink color
115 in the well after 1 hour of incubation of the plate at 37°C.

116

117 **Determination of Anti-inflammatory Activity**

118 The 1% (v/v) formalin-induced edema model is a classic paradigm of acute local biphasic inflammation described
119 by Sen et al. (1991). Rats were divided into four (4) groups of three (3) rats per group. The rats were fasted for 12 h
120 prior to the experiment. The initial thickness (T0) of the left hind leg of each rat/group was measured. Subsequently,
121 a volume of 0.1 ml of 1% formalin was injected into the plantar fascia of the rats' feet. Leg thickness measurements
122 were taken hourly from 1 to 4 h after formalin injection using a digital caliper (0.01 mm accuracy). Two control
123 groups were prepared for the experiment. These were:

124 - Lot 1: negative control that received formalin without being treated;
125 - Lot 2: positive control which was treated with the reference product, here acetylsalicylic acid.

126 Thirty (30) minutes before the formalin injection, the rats to be tested received orally 300 mg/kg of hydroethanolic
127 extracts of the leaves of *Smeathmannia laevigata* and *Mussaenda elegans* respectively. Aspirin (acetylsalicylic acid)

128 was used as the reference product at a dose of 100 mg/kg. The negative control group received 0.9% isotonic saline
129 NaCl (10 ml/kg).

130

131 **Table 1: Experimental groups** (random allocation):

Batch	Band	Treatment	Dose	Way
Lot 1	Negative test	saline solution	0.9% NaCl (10 ml/kg)	Oral
Lot 2	Positive test	Acetylsalicylic acid	100 mg/kg	Oral
Lot 3	<i>Mussaenda elegans</i>	Tested extract/compound	300mg/kg	Oral
Lot 4	<i>Smeathmannia laevigata</i>	Tested extract/compound	300 mg/kg	Oral

132
133 The percentage increase (P) and inhibition (I) of edema were calculated using the following formulas:

134
$$P = \frac{V_t - V_o}{V_o} \times 100$$

135 With

136 P: percentage increase in edema

137 V_o = volume of the right hind leg at time 0 (before treatment)

138 V_t = volume of the right hind leg at time t

139

140

141 • (%) Inhibition :

142

143
$$I = \frac{(PAO) \text{ groupe contrôle} - (PAO) \text{ groupe traité}}{(PAO) \text{ groupe contrôle}} \times 100$$

144

145 I: Percentage of edema inhibition

146

147 **Statistical analysis**

148 The data were entered into an Excel spreadsheet. Mean values \pm SEM and one-way ANOVA followed by Tukey's
149 test ($p < 0.05$) were calculated using software (e.g., GraphPad Prism v.8).

150

151 **Results and discussion**152 **Phytochemical study**153 Table 1 presents the results of the phytochemical analysis of the hydroethanolic extract of plant material from
154 *Mussaenda elegans* and *Smeathmannia laevigata* .155 **Table 1: Phytochemical screening of the two plants**

Secondary metabolites	Plants	
	<i>Mussaenda elegans</i>	<i>Smeathmannia laevigata</i>
Anthraquinone	-	-
Mucilage	+	-
Tannins	+	+
Flavonoids	+	+
Saponins	+	-
Alkaloids	-	-
Reducing compounds	+	+

156 - : Absent; + : Present

157 Phytochemical analysis of plant material from *Mussaenda elegans* and *Smeathmannia laevigata* reveals the presence
158 of several secondary metabolites, including phenols, tannins, and flavonoids. Nwafor et al. (2022) identified
159 alkaloids, tannins, flavonoids, saponins, and reducing compounds in *M. elegans* leaves harvested in Nigeria. Their
160 results are nearly identical to those of our work, with the difference that these authors demonstrated the presence of
161 alkaloids in this plant, unlike our findings.

162 The total estimated content of phenolic compounds, flavonoids and tannins is presented in Table 2.

163 **Table 2: Phenolic compound content**

Extract	Total phenolics (mg AG/g)	Flavonoid (mg EQ/g)	Tannins (mg EC/g)
<i>M. elegans</i>	22.006 ± 0.648	2.360 ± 0.110	4.087 ± 0.312
<i>S. laevigata</i>	11.239 ± 0.422	0.940 ± 0.052	9.945 ± 0.622

164

165 *Mussaenda elegans* plant material has a significantly higher phenol content (22.006 ± 0.648 mg GA/g) than the
166 hydroethanolic extract of *Smeathmannia laevigata* plant material (11.239 ± 0.422 mg GA/mg). The same
167 observation was made for flavonoid content (2.360 ± 0.110 mg QE/g for *Mussaenda elegans* versus 0.940 ± 0.052
168 mg QE/g for *Smeathmannia laevigata*, and the opposite was found for tannin content for which content was 4.087 ±
169 0.312 mg CE/g for *Mussaenda elegans* versus 9.945 ± 0.622 mg EC/g for *Smeathmannia laevigata*. These
170 observations suggest that the hydroethanolic extract of *Mussaenda elegans* plant material has superior biological
171 potential, particularly in terms of antibacterial and anti-inflammatory activities, compared to the hydroethanolic
172 extract of *Smeathmannia laevigata* plant material.173 Nwafor et al. (2022) found respective total phenol, flavonoid, and tannin levels of 659.75, 34.13, and 304.11 mg/100
174 g, or approximately 6.59, 0.34, and 3.04 mg/g. Compared to the results of our work, the tannin contents are similar,
175 while the total phenol and flavonoid contents found by these authors are lower than those of our work. Hassler
176 (2025) showed that *Rosa laevigata* is synonymous with *Smeathmannia laevigata*. According to Quan et al. (2022) ,
177 approximately 148 chemical components have been isolated from this plant, including flavonoids, lignans,
178 polyphenols, steroids, triterpenoids, tannins, and other components.

179

180 **Antimicrobial activity**

181 Table 3 presents the antibacterial activity of the plant extracts studied. Analysis of this table shows that the
 182 hydroethanolic extracts of *S. laevigata* and *M. elegans* both exhibited inhibitory activity against the tested microbial
 183 strains, with MICs ranging from 1.25 to 10 mg/mL. The hydroethanolic extract of *M. elegans* proved particularly
 184 effective against *Pseudomonas aeruginosa* and *Staphylococcus aureus* with an MIC of 1.25 mg/mL. The
 185 hydroethanolic extract of *S. laevigata* was more effective against *Escherichia coli*, with an MIC of 2.5 mg/mL.
 186 Pharmacological studies have already confirmed that the leaves of *Rosa laevigata*, synonym of *S. laevigata*, have
 187 antioxidant, anti-inflammatory, antiviral and antitumor activities (Quan et al., 2022).

188

189 **Table 3: Minimum Inhibitory Concentration (MIC)**

Microbial strains	MIC (mg/mL)	
	<i>S. laevigata</i>	<i>M. elegans</i>
<i>Salmonella typhi</i>	5	5
<i>Escherichia coli</i>	2.5	5
<i>Pseudomonas aeruginosa</i>	2.5	1.25
<i>Staphylococcus aureus</i>	10	1.25
<i>Candida albicans</i>	2.5	2.5
<i>Enterococcus faecalis</i>	5	5

190

191

192 **Anti-inflammatory activity**

193 Figure 1 shows the anti-inflammatory activity of extracts from the two plants studied, as well as aspirin taken as a
 194 reference compound

195 .

196


197

198

199

200

201



202

203

204

205

206 **Figure 1:** Edema-inhibiting power of the tested extracts and reference compound

207 In a 1% formalin-induced rat leg edema model reproducing the acute and late phases of inflammation, extracts of
208 *Smeathmannia laevigata* and *Mussaenda elegans* showed moderate anti-inflammatory activity, although lower than
209 that of the pharmacological standard. Post-hoc statistical analysis using Tukey's test, performed after ANOVA,
210 revealed a significant superiority of the aspirin-treated positive control, with a mean inhibition of 34.49%, compared
211 to the *Smeathmannia laevigata* extract (10.25% inhibition; $p = 0.0358$). In contrast, the difference observed between
212 aspirin and the *Mussaenda elegans* extract (18.29% inhibition) did not reach statistical significance ($p = 0.0667$).
213 Furthermore, direct comparison between extracts of *Smeathmannia laevigata* and *Mussaenda elegans* revealed no
214 statistically significant difference (mean difference: 8.04%; $p = 0.3752$), although *Mussaenda elegans* showed a
215 tendency towards greater efficacy.

216 The anti-inflammatory activity observed for these two extracts could be linked to a partial inhibition of
217 prostaglandin synthesis via the cyclooxygenase-2 (COX-2) pathway, associated with modulation of pro-
218 inflammatory cytokines such as TNF- α , IL-1 β , and IL-6, possibly under the control of the NF- κ B signaling pathway.
219 These results position the extracts of *Smeathmannia laevigata* and *Mussaenda elegans* as promising
220 natural candidates for developing alternatives to conventional non-steroidal anti-inflammatory drugs (NSAIDs),
221 although their efficacy remains below the reference standard and requires further investigation to confirm their
222 therapeutic potential and safety profile. The phytochemicals primarily responsible for the anti-inflammatory
223 activities belong to the families of polyphenols, terpenoids, flavonoids, saponins, and tannins (Azab et al., 2016;
224 Bunte et al., 2019; N'guessan et al., 2021). The fact that the phenolic compound content of the two plants is
225 comparable to their anti-inflammatory activity could mean that the anti-inflammatory activity observed in both
226 plants could be largely due to these phenolic compounds.

227

228 Conclusion

229 In conclusion, this study suggests that the leaves of *Smeathmannia laevigata* and *Mussaenda elegans* are two
230 potential sources of bioactive molecules. This observation is supported by the phenolic compound content of these
231 two plants, which correlates with their antimicrobial and anti-inflammatory activities. Further investigations are

232 warranted on these two plants to identify the secondary metabolites responsible for their biological activity and to
233 assess their potential toxicity.

234

235 **Reference**

236 Atindehou, M., Lagnika, L., Guérol, B., Strub, J.M., Zhao M., Van Dorsselaer, A., et al. (2013) Isolation and
237 Identification of Two Antibacterial Agents from *Chromolaena odorata* L. Active against Four Diarrheal Strains.
238 *Advances in Microbiology*, 3, 115-121.

239 Azab A., Nassar A., Azab A.N., (2016). Anti-Inflammatory Activity of Natural Products Molecules, 21, 1-13

240 Bah TV, Camara AK, Camara KM, Diane S., Doumbouya AD, Sacko S., ... & Balde ES (2025). Ethnobotanical
241 survey of medicinal plants used in the management of infertility in Lower Guinea and Forest Guinea.
242 *Pharmacopoeia and Traditional African Medicine*, 23(2), 34-44.

243 Blain, H., Jouzeau, JY, Netter, P., & Jeandel, C. (2000). Therapeutic movement: Non-steroidal anti-inflammatory
244 drugs that are selective cyclooxygenase 2 inhibitors. Interest and perspectives. In *Rev Méd Interne* (Vol. 21).

245 Camara AK, Keita, T., Tonguino, TG, Kourouma, A., Kolie, A., Soumah, A., ... & Traore, MS (2023).
246 Ethnobotanical survey on the use of medicinal plants in the treatment of oral and dental conditions in the commune
247 of Kindia in the Republic of Guinea. *Pharmacopoeia and traditional African medicine*, 21(2), 107-115.

248 Camara MK, Camara AK, Bangoura MD, Diane S., Loua J., Traore MS, & Balde AM (2024). Ethnobotanical study
249 of plants used in the traditional treatment of hemorrhoids in the Kpèlè (Lola) community, Guinea. *Pharmacopoeia*
250 and African Traditional Medicine, 23(1), 146-159.

251 Goumou, K., Haba, NL, Traoré, MS, Bah, F., & Balde, MA (2022). Ethnobotanical survey on the use of medicinal
252 plants in the traditional treatment of dermatoses in Guinea. *Pharmacopoeia and traditional African medicine* , 21
253 (1), 50-65.

254 Haba NL, Goumou K., Camara A., Traoré MS, Balde ES, & Balde, AM (2022). Contribution to the knowledge of
255 medicinal plants used in the traditional treatment of malaria in Forest Guinea. *Pharmacopoeia and traditional*
256 *African medicine*, 21(1), 78-88.

257 Hassler M. (1994 - 2025): World Plants. Synonymic Checklist and Distribution of the World Flora. Version 25.12;
258 last update Dec. 21st, 2025. -

259 Klobucar, K., & Brown, E. D. (2022). New potentiaters of ineffective antibiotics: Targeting the Gram-negative outer
260 membrane to overcome intrinsic resistance. In *Current Opinion in Chemical Biology* (Vol. 66). Elsevier Ltd.
261 <https://doi.org/10.1016/j.cbpa.2021.102099>

262 Koudoro YA, Awadji JM, Botezatu DA, Olayé T., Agbangnan Dossa CP, Alitonou GA, Avlessi F., Dinica RM and
263 Sohounhloue CKD, (2021). Phytochemical analysis, antioxidant and anti-inflammatory activities of *Chassalia kolly*
264 leaves extract, a plant used in Benin to treat skin illness; *GSC Biological and Pharmaceutical Sciences*, 15(03), 063–
265 072.

266 Mack, M. (2018). Inflammation and fibrosis. In *Matrix Biology* (Vols. 68–69, pp. 106–121). Elsevier BV
267 <https://doi.org/10.1016/j.matbio.2017.11.010>

268 Nathan, C., & Ding, A. (2010). Nonresolving Inflammation. In *Cell* (Vol. 140, Issue 6, pp. 871–882). Elsevier B.V.
269 <https://doi.org/10.1016/j.cell.2010.02.029>

270 Noudogbessi J.P.A., Natta A.K., Tchobo F.P., Bogninou G.S., Bothon F.T.D., Bossou et al., 2013. Phytochemical
271 Screening of *Pentadesma butyracea* Sabine (Clusiaceae) Acclimated in Benin by GC/MS. Hindawi Publishing
272 Corporation ISRN Analytical Chemistry. Volume 2013, Article ID 172397, 8 pages

273 Nwafor, F. I., Ogbonna, C. E., Igwe, U. I., Nwosu, M. O., & Inya-Agha, S. I. (2022). Chemotaxonomic significance
274 and environmental implications of the phytochemical constituents of four *Mussaenda* L.(Rubiaceae) taxa in
275 Nigeria.Journal of Experimental Biology and Agricultural Sciences, 10(4), 861 – 869.

276 Olayé T., Tchobo F.P. and Chabi,N.W. (2018). Phytochemical potential, antiradical and antimicrobial activity of
277 crude extracts of *Caesalpinia benthamiana* roots used for oral hygiene in Benin republic. Journal of Pharmacognosy
278 and Phytochemistry 2018; 7(5): 1939-1944

279 Prasad, P., Gupta, A., & Sasmal, P. K. (2021). Aggregation-induced emission active metal complexes : A promising
280 strategy to tackle bacterial infections. Chemical Communications, 57(2), 174–186.
281 <https://doi.org/10.1039/d0cc06037b>

282 N'guessan BB, Asiamah AD, Arthur NK, Frimpong-Manso S., Amponsah SK, Kukuia KE, Sarkodie
283 JA, Opuni KFM, Asiedu-Gyekye IJ (2021). Ethanolic Extract of *Nymphaea lotus* L. (Nymphaeaceae) Leaves
284 Exhibits in Vitro Antioxidant, in Vivo Anti-Inflammatory and Cytotoxic Activities on Jurkat and MCF-7 Cancer
285 Cell Lines ; BMC Complement. Med. Ther., 21, 1-13.

286